Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform
Gothenburg, July 11, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK[TM], today announced that it has received a Communication under Rule 71(3) EPC (“Notice of Allowance”) from the European Patent Office in its European patent application relating to the use of the iTANK[TM] technology in CAR T-cell therapies.The Communication means that the European Patent